Avalyn Pharma Wants to Breathe New Life Into the IPO Market

Still Climbing the Clinical Ladder

Before anyone gets too excited, some important context. AP01 is not yet in Phase 3 trials. The ongoing MIST Phase 2b study is currently enrolling up to 300 patients across three arms (high dose, low dose, and placebo) over 52 weeks. The primary goal: measuring changes in forced vital capacity, a standard test of how much air your lungs can push out.

Avalyn also has AP02, an inhaled version of nintedanib (the other approved IPF drug, sold as Ofev). That program just dosed its first patient in a Phase 2 trial called AURA in March 2026. Behind both sits AP03, a combination of both drugs in inhaled form, still in preclinical work.

So the IPO money isn't funding late-stage trials that are already running. It's funding the next step: the expensive Phase 3 trials that, if successful, would pave the road to FDA approval. The company reported zero revenue and an $85.2 million net loss for 2025, which is perfectly normal for a pre-revenue biotech but underscores why the cash infusion matters.

Why the Timing Is Interesting

Avalyn isn't just betting on its science. It's betting on the IPO window staying open.

Biotech IPOs had a rough stretch. But Q1 2026 showed signs of a thaw: biotech IPOs raised $1.7 billion across a handful of deals, the highest quarterly total since 2021. The median raise jumped to $287.5 million, more than double Q1 2025 levels.

The catch? Investors are picky. No preclinical-stage company has successfully IPO'd since 2024. The companies getting funded have a specific profile: lots of prior venture backing, mid- to late-stage clinical programs, and focus areas that Wall Street finds exciting. Expectations for the 2026 IPO market are still modest.

Avalyn checks some of those boxes. The company has raised more than $275 million in private funding across 18 venture and healthcare investors, including a $100 million oversubscribed Series D in July 2025. CEO Lyn Baranowski brings credibility from her time at Pearl Therapeutics (sold to AstraZeneca for $1.15 billion in 2013) and Altavant Sciences (acquired by Sumitomo Dainippon in 2019).

But the company is still in Phase 2, not Phase 3. That's a riskier profile than what's been clearing the IPO bar lately.

A Crowded Market With Room for Something Different

The IPF drug market is large and growing at a healthy clip. New entrants like Boehringer Ingelheim's nerandomilast (a PDE4B inhibitor called Jascayd) are entering the market alongside established players like Ofev (nintedanib) and Esbriet (pirfenidone), which is losing ground to generics.

Then there's United Therapeutics' Tyvaso, an inhaled treprostinil that could get an expanded FDA label for IPF by mid-2026. Tyvaso would be used alongside existing oral drugs, not instead of them, which sets an interesting precedent for inhaled therapies as a complement rather than a replacement.

Avalyn's approach is different. AP01 and AP02 aren't new molecules; they're new delivery methods for proven drugs. If the inhaled versions can match or beat oral efficacy while slashing side effects, the commercial case writes itself. Patients stick with treatments they can tolerate. Doctors prescribe drugs that patients actually take.

The Bottom Line

Avalyn's IPO is a bet layered on top of a bet. The first bet: that inhaled pirfenidone and nintedanib can replicate their promising early data in larger, longer trials. The second bet: that public investors will fund a Phase 2 company in a market that's been rewarding only the most de-risked stories.

The science is compelling. Lung function data from ATLAS is genuinely eye-catching, and the long-term safety profile (some patients have been on AP01 for over three years with no new red flags) adds confidence. But Phase 2b results from MIST haven't dropped yet, and that's the dataset that will really tell the story.

For Avalyn, the next few months are a double audition: convincing investors to buy the stock and convincing regulators the data justifies a Phase 3 green light. In biotech, nailing both at the same time is like threading a needle on a roller coaster. But if the company pulls it off, patients with scarred lungs might finally get a treatment they don't have to choose between tolerating and abandoning.

Gilead's $45M Bet on a Drug That Destroys Cancer Proteins

Gilead just paid $45 million to license a cancer drug that doesn't block bad proteins; it destroys them entirely. The Kymera Therapeutics deal could be worth up to $750 million, and it's part of a much bigger bet on protein degradation reshaping oncology.